Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation therapy plus QL1706 in unresectable advanced hepatocellular carcinoma
ChiCTR2600126661Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of QL1706 in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Objective Response Rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600126661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126661.